Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 18Thoracic 5Genitourinary 5Dermatologic 4Gastrointestinal 3Gynecologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 163Breast Neoplasms 162Carcinoma, Non-Small-Cell Lung 60Melanoma 44Ovarian Neoplasms 42Colorectal Neoplasms 37Carcinoma, Renal Cell 36Squamous Cell Carcinoma of Head and Neck 33Pancreatic Neoplasms 29Stomach Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 24Neoplasms 24Endometrial Neoplasms 24Lung Neoplasms 19Head and Neck Neoplasms 19Esophageal Neoplasms 18Carcinoma, Transitional Cell 18Carcinoma, Hepatocellular 16Urinary Bladder Neoplasms 14Small Cell Lung Carcinoma 14Prostatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Sarcoma 10Mesothelioma 9Kidney Neoplasms 9Cholangiocarcinoma 9Carcinoma, Ovarian Epithelial 9Carcinoma, Merkel Cell 9Fallopian Tube Neoplasms 8

Interventions

pembrolizumab 2Fluorodeoxyglucose F18 2motexafin gadolinium 1fluoromisonidazole 1Vorinostat 1Taxes 1Rubidium-82 1Ritonavir 1Radiotherapy 1Polymerase Chain Reaction 1Nivolumab 1Magnetic Resonance Spectroscopy 1Indinavir 1Immunohistochemistry 1Gene Expression Profiling 1Fluorescent Antibody Technique 1Flow Cytometry 1FPP(RGD)2 1Drug Therapy 1Doxorubicin 1Biopsy 15-fluoropentyl-2-methylmalonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × pembrolizumab × Breast × Clear all
NCT03589339 2025-10-24

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Nanobiotix

Phase 1 Active not recruiting
145 enrolled
BreastGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mouth Neoplasms, Oropharyngeal Neoplasms, Triple Negative Breast Neoplasms

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡